{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:05:58Z","timestamp":1779523558906,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01497-9","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:49:57Z","timestamp":1779522597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal First-line Immune-related Therapy Selection for Advanced Gastric Cancer: A Systematic Review and Network Meta-analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Di","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beian","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-4482","authenticated-orcid":false,"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"3","key":"1497_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1497_CR2","doi-asserted-by":"publisher","first-page":"189277","DOI":"10.1016\/j.bbcan.2025.189277","volume":"1880","author":"J Song","year":"2025","unstructured":"Song J, Zhu J, Jiang Y, Guo Y, Liu S, Qiao Y, et al. Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies. Biochim Biophys Acta Rev Cancer. 2025;1880(2):189277.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1497_CR3","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"issue":"21","key":"1497_CR4","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023;330(21):2064\u201374.","journal-title":"JAMA"},{"issue":"11","key":"1497_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"1497_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"key":"1497_CR7","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang J, Wang G, Zhang Y, Fan Q, Lu C, et al. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial. JAMA. 2025;333(15):1305\u201314.","DOI":"10.1001\/jama.2024.28463"},{"issue":"7","key":"1497_CR8","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao X, Ji K, Jia Y, Shan F, Chen Y, Xu N, et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial. Nat Med. 2024;30(7):1943\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"1497_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12916-022-02605-9","volume":"20","author":"D Liu","year":"2022","unstructured":"Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, et al. Bifunctional anti-PD-L1\/TGF-\u03b2RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. BMC Med. 2022;20(1):408.","journal-title":"BMC Med"},{"issue":"1","key":"1497_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12957-025-03752-y","volume":"23","author":"Z Chen","year":"2025","unstructured":"Chen Z, Ma Y, Chen J. Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives. World J Surg Oncol. 2025;23(1):92.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1497_CR11","doi-asserted-by":"publisher","first-page":"100189","DOI":"10.1016\/j.esmoop.2021.100189","volume":"6","author":"E Van Cutsem","year":"2021","unstructured":"Van Cutsem E, Valderrama A, Bang YJ, Fuchs CS, Shitara K, Janjigian YY, et al. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric\/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. ESMO Open. 2021;6(4):100189.","journal-title":"ESMO Open"},{"issue":"6","key":"1497_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"N Boku","year":"2024","unstructured":"Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, et al. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer. 2024;27(6):1287\u2013301.","journal-title":"Gastric Cancer"},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"S1249","DOI":"10.1016\/j.annonc.2024.08.2301","volume":"35","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, Goetze TO, Thuss-Patience PC, Riera Knorrenschild J, Goekkurt E, Dechow TN, et al. LBA59 Modified FOLFOX plus\/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial. Ann Oncol. 2024;35:S1249\u201350.","journal-title":"Ann Oncol"},{"issue":"17","key":"1497_CR14","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.23.01636","volume":"42","author":"S Hegewisch-Becker","year":"2024","unstructured":"Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, et al. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. J Clin Oncol. 2024;42(17):2080\u201393.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1497_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1497_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13000-021-01099-y","volume":"16","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang Y, Li Z, Lin D, Liu Y, Zhou L, et al. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. Diagn Pathol. 2021;16(1):38.","journal-title":"Diagn Pathol"},{"key":"1497_CR17","doi-asserted-by":"crossref","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31(4):1163\u201370.","DOI":"10.1038\/s41591-024-03450-4"},{"issue":"1","key":"1497_CR18","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15(1):2180794.","journal-title":"MAbs"},{"issue":"14","key":"1497_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"1497_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31\u201341.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1497_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.","journal-title":"J Exp Clin Cancer Res"},{"key":"1497_CR22","doi-asserted-by":"publisher","first-page":"111046","DOI":"10.1016\/j.biopha.2020.111046","volume":"134","author":"CY Huang","year":"2021","unstructured":"Huang CY, Chung CL, Hu TH, Chen JJ, Liu PF, Chen CL. Recent progress in TGF-\u03b2 inhibitors for cancer therapy. Biomed Pharmacother. 2021;134:111046.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1497_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","volume":"22","author":"M Yang","year":"2024","unstructured":"Yang M, Cui M, Sun Y, Liu S, Jiang W. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Commun Signal. 2024;22(1):338.","journal-title":"Cell Commun Signal"},{"issue":"8","key":"1497_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1497_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737140.2023.2238896","volume":"23","author":"M Noori","year":"2023","unstructured":"Noori M, Fayyaz F, Zali MR, Bashash D. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2023;23(9):1029\u201339.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"1497_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1497_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/s12916-024-03801-5","volume":"22","author":"X Zhang","year":"2024","unstructured":"Zhang X, Dai X, Liu A, Sun M, Cong L, Liang J, et al. Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study. BMC Med. 2024;22(1):585.","journal-title":"BMC Med"},{"issue":"4suppl","key":"1497_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JCO.2025.43.4_suppl.414","volume":"43","author":"M Qiu","year":"2025","unstructured":"Qiu M, Luo H, Wang F-H, Wang F, He M-M, Xu S, et al. Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric\/gastroesophageal junction adenocarcinoma (GC\/GEJC) patients with\/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study. J Clin Oncol. 2025;43(4suppl):414.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1497_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","volume":"28","author":"JC Lee","year":"2022","unstructured":"Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. The Liver-Immunity Nexus and Cancer Immunotherapy. Clin Cancer Res. 2022;28(1):5\u201312.","journal-title":"Clin Cancer Res"},{"issue":"4suppl","key":"1497_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1200\/JCO.2025.43.4_suppl.335","volume":"43","author":"Z Peng","year":"2025","unstructured":"Peng Z, Wang J, Zhang Y, Li H, Zhao Q, Zhu X, et al. Effect of SHR-1701 on chemotherapy (chemo)-induced myelosuppression: Data from a phase 3 study in HER2-negative gastric\/gastroesophageal junction adenocarcinoma (G\/GEJA). J Clin Oncol. 2025;43(4suppl):335.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1497_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43\u201350.","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01497-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:50:00Z","timestamp":1779522600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01497-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01497-9","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}